Stock MITRA MITHRA PHARMACEUTICALS S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Mithra Pharmaceuticals S.A.

Equities

MITRA

BE0974283153

Real-time Euronext Bruxelles
Other stock markets
 11:35:26 2024-04-26 am EDT 		5-day change 1st Jan Change
0.216 EUR -1.82% Intraday chart for Mithra Pharmaceuticals S.A. -.--% -82.78%
Apr. 29 Mithra Pharmaceuticals to Postpone the Publication of Its Annual Report 2023 CI
Apr. 22 Mithra Pharmaceuticals Obtains Court Protection Measures MT

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.
  • One of the major weak points of the company is its financial situation.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • Most analysts recommend that the stock should be sold or reduced.
  • The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.
  • Over the past twelve months, analysts' opinions have been revised negatively.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
MITHRA PHARMACEUTICALS S.A. Stock Mithra Pharmaceuticals S.A.
-82.78% 16.2M
C+
CSL LIMITED Stock CSL Limited
-2.10% 90.02B
A-
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
-1.18% 39.15B
A-
BIOGEN INC. Stock Biogen Inc.
-15.83% 31.71B
B-
UCB Stock UCB
+62.29% 26.47B
A
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-21.68% 14.34B
C
INCYTE CORPORATION Stock Incyte Corporation
-8.73% 12.89B
B-
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-10.32% 11.18B
D+
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-45.69% 10.97B
B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+3.67% 8.94B
B+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy
  1. Stock Market
  2. Equities
  3. MITRA Stock
  4. Ratings Mithra Pharmaceuticals S.A.